- Home
- PRLD vs IKT Comparison
PRLD vs IKT Comparison
Compare PRLD & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRLD | IKT |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 218.0M | 240.1M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRLD | IKT |
|---|---|---|
| Price | $4.52 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $5.67 | $5.00 |
| AVG Volume (30 Days) | 415.0K | ★ 1.0M |
| Earning Date | 05-13-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 23.21 | ★ 57.76 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,140,000.00 | N/A |
| Revenue This Year | $320.10 | N/A |
| Revenue Next Year | $100.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 73.43 | N/A |
| 52 Week Low | $0.73 | $1.33 |
| 52 Week High | $5.54 | $2.37 |
Technical Indicators
Market Signals| Indicator | PRLD | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 57.45 | 55.52 |
| Support Level | $1.09 | $1.43 |
| Resistance Level | $5.54 | $1.88 |
| Average True Range (ATR) | 0.65 | 0.12 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 38.30 | 78.12 |
Price Performance
Historical ComparisonAbout PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.